HopeStage
Back to all studies
CompletedNCT00644969

Varenicline or placebo with counseling to stop smoking in schizophrenia

About this titleRead the official source — NCT00644969
Medication studyAges 18–75United States + Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 75 years.

Listed locations
Aurora and 13 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2008
Recruitment status
Completed
Enrollment listed in the registry
128
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 18 Years to 75 Years
Official registry ID
NCT00644969
Official title
Show the full official title

A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Aurora, United States · Farmington, United States · New Haven, United States

9 more locations
  • Worcester, United States
  • New Brunswick, United States
  • Durham, United States
  • Cincinnati, United States
  • Pittsburgh, United States
  • Houston, United States
  • Edmonton, Canada
  • Mississauga, Canada
  • Toronto, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including placebo and varenicline (CP-526,555).

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies